Fremanezumab (Ajovy)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Fremanezumab

What it is

Fremanezumab is a biologic medicine, a monoclonal antibody that binds CGRP, a signalling molecule released during migraine attacks that widens blood vessels and transmits pain. Injected monthly or every three months, it is used to prevent migraine in adults. It is sold as Ajovy.

How genes come into it

As an antibody, fremanezumab is not broken down by drug-processing enzymes. Studies have looked at genes of the CGRP receptor complex (CALCRL, CRCP) and at CALCR and COMT for who responds. The findings come from a few small studies, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Fremanezumab. Upload your DNA file to see which of these rows apply to you.

Rated evidence (2 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

COMT rs4680: Level 3. Efficacy: Migraine with Aura, Migraine without Aura. 1.

rs12615320: Level 3. Efficacy: Migraine with Aura, Migraine without Aura. 1.

Response (8 findings)

Studies of how well it worked in people carrying a variant.

rs12615320: Allele G is associated with decreased response to erenumab, fremanezumab or galcanezumab in people with Migraine without Aura or Migraine with Aura as compared to allele A.

CALCR rs12672399: Allele C is not associated with response to erenumab, fremanezumab or galcanezumab in people with Migraine without Aura or Migraine with Aura as compared to allele T.

CALCR rs4470942: Allele G is not associated with response to erenumab, fremanezumab or galcanezumab in people with Migraine without Aura or Migraine with Aura as compared to allele A.

CALCR rs75252614: Allele G is not associated with response to erenumab, fremanezumab or galcanezumab in people with Migraine without Aura or Migraine with Aura as compared to allele C.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Aimovig (CGRP Antagonists)

Emgality (CGRP Antagonists)

Abilify (Antipsychotics)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com